Control of cytokine production by human Fc gamma receptors: Implications for pathogen defense and autoimmunity

Frontiers in Immunology

Volumn 6, Issue FEB, 2015, Pages

  Vogelpoel, Lisa T C ^a   Baeten, Dominique L P ^a   de Jong, Esther C ^a   den Dunnen, Jeroen ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Antibacterial response; Cross talk; Dendritic cells; Fc RII ; Macrophages; Rheumatoid arthritis; Systemic lupus erythematosus; TNFa

Indexed keywords

CYTOKINE; FC RECEPTOR; FC RECEPTOR I; FC RECEPTOR IIA; FC RECEPTOR IIB; FC RECEPTOR IIC; FC RECEPTOR IIIA; FC RECEPTOR IIIB; IMMUNOGLOBULIN G; PROINFLAMMATORY CYTOKINE; PROTEIN TYROSINE PHOSPHATASE SHP 1; UNCLASSIFIED DRUG;

AUTOIMMUNITY; BACTERIAL INFECTION; COMPLEMENT ACTIVATION; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNORECEPTOR TYROSINE BASED ACTIVATION MOTIF; MYCOSIS; OPSONIZATION; PARASITOSIS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; VIRUS INFECTION;

EID: 84926612756     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00079     Document Type: Review

References (98)

1. Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science (2010) 327:291-5. doi: 10.1126/science.1183021
2. Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol (2014) 5:520. doi:10.3389/fimmu.2014.00520
3. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol (2008) 8:34-47. doi:10.1038/nri2206
4. Guilliams M, Bruhns P, Saeys Y, Hammad H, Lambrecht BN. The function of Fcgamma receptors in dendritic cells and macrophages. Nat Rev Immunol (2014) 14:94-108. doi:10.1038/nri3582
5. Lux A, Nimmerjahn F. Of mice and men: the need for humanized mouse models to study human IgG activity in vivo. J Clin Immunol (2013) 33(Suppl 1):S4-8. doi:10.1007/s10875-012-9782-0
6. den Dunnen J, Vogelpoel LT, Wypych T, Muller FJ, de BL, Kuijpers TW, et al. IgG opsonization of bacteria promotes Th17 responses via synergy between TLRs and FcgammaRIIa in human dendritic cells. Blood (2012) 120:112-21. doi:10.1182/blood-2011-12-399931
7. Vogelpoel LT, Hansen IS, Visser MW, Nagelkerke SQ, Kuijpers TW, Kapsenberg ML, et al. FcgammaRIIa cross-talk with TLRs, IL-1R, and IFNgammaR selectively modulates cytokine production in human myeloid cells. Immunobiology (2015) 220:193-9. doi:10.1016/j.imbio.2014.07.016
8. Boruchov AM, Heller G, Veri MC, Bonvini E, Ravetch JV, Young JW. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J Clin Invest (2005) 115:2914-23. doi:10.1172/JCI24772
9. Blom AB, Radstake TR, Holthuysen AE, Sloetjes AW, Pesman GJ, Sweep FG, et al. Increased expression of Fcgamma receptors II and III on macrophages of rheumatoid arthritis patients results in higher production of tumor necrosis factor alpha and matrix metalloproteinase. Arthritis Rheum (2003) 48:1002-14. doi:10.1002/art.10871
10. Radstake TR, Blom AB, Sloetjes AW, van Gorselen EO, Pesman GJ, Engelen L, et al. Increased FcgammaRII expression and aberrant tumour necrosis factor alpha production by mature dendritic cells from patients with active rheumatoid arthritis. Ann Rheum Dis (2004) 63:1556-63. doi:10.1136/ard.2003.016550
11. Nuutila J, Jalava-Karvinen P, Hohenthal U, Kotilainen P, Pelliniemi TT, Nikoskelainen J, et al. A rapid flow cytometric method for distinguishing between febrile bacterial and viral infections. J Microbiol Methods (2013) 92:64-72. doi:10.1016/j.mimet.2012.11.005
12. Aloulou M, Ben Mkaddem S, Biarnes-Pelicot M, Boussetta T, Souchet H, Rossato E, et al. IgG1 and IVIg induce inhibitory ITAM signaling through FcgammaRIII controlling inflammatory responses. Blood (2012) 119:3084-96. doi:10.1182/blood-2011-08-376046
13. Ben Mkaddem S, Hayem G, Jonsson F, Rossato E, Boedec E, Boussetta T, et al. Shifting FcgammaRIIA-ITAM from activation to inhibitory configuration ameliorates arthritis. J Clin Invest (2014) 124:3945-59. doi:10.1172/JCI74572
14. Vogelpoel LT, Hansen IS, Rispens T, Muller FJ, van Capel TM, Turina MC, et al. Fc gamma receptor-TLR cross-talk elicits pro-inflammatory cytokine production by human M2 macrophages. Nat Commun (2014) 5:5444. doi:10.1038/ncomms6444
15. Huang ZY, Hunter S, Kim MK, Indik ZK, Schreiber AD. The effect of phosphatases SHP-1 and SHIP-1 on signaling by the ITIM-and ITAM-containing Fcγreceptors FcγRIIB and FcγRIIA. J Leukoc Biol (2003) 73:823-9. doi:10.1189/jlb.0902454
16. Blank U, Launay P, Benhamou M, Monteiro RC. Inhibitory ITAMs as novel regulators of immunity. Immunol Rev (2009) 232:59-71. doi:10.1111/j.1600-065X.2009.00832.x
17. Banki Z, Kacani L, Mullauer B, Wilflingseder D, Obermoser G, Niederegger H, et al. Cross-linking of CD32 induces maturation of human monocyte-derived dendritic cells via NF-kappa B signaling pathway. J Immunol (2003) 170:3963-70. doi:10.4049/jimmunol.170.8.3963
18. Dhodapkar KM, Banerjee D, Connolly J, Kukreja A, Matayeva E, Veri MC, et al. Selective blockade of the inhibitory Fcgamma receptor (FcgammaRIIB) in human dendritic cells and monocytes induces a type I interferon response program. J Exp Med (2007) 204:1359-69. doi:10.1084/jem.20062545
19. Dai X, Jayapal M, Tay HK, Reghunathan R, Lin G, Too CT, et al. Differential signal transduction, membrane trafficking, and immune effector functions mediated by FcgammaRI versus FcgammaRIIa. Blood (2009) 114:318-27. doi:10.1182/blood-2008-10-184457
20. Dhodapkar KM, Kaufman JL, Ehlers M, Banerjee DK, Bonvini E, Koenig S, et al. Selective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. Proc Natl Acad Sci U S A (2005) 102:2910-5. doi:10.1073/pnas.0500014102
21. Ivashkiv LB. How ITAMs inhibit signaling. Sci Signal (2011) 4:e20. doi:10.1126/scisignal.2001917
22. Pfirsch-Maisonnas S, Aloulou M, Xu T, Claver J, Kanamaru Y, Tiwari M, et al. Inhibitory ITAM signaling traps activating receptors with the phosphatase SHP-1 to form polarized "inhibisome" clusters. Sci Signal (2011) 4:ra24. doi:10.1126/scisignal.2001309
23. Ambarus CA, Santegoets KC, van Bon L, Wenink MH, Tak PP, Radstake TR, et al. Soluble immune complexes shift the TLR-induced cytokine production of distinct polarized human macrophage subsets towards IL-10. PLoS One (2012) 7:e35994. doi:10.1371/journal.pone.0035994
24. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity (2011) 34:637-50. doi:10.1016/j.immuni.2011.05.006
25. Nish S, Medzhitov R. Host defense pathways: role of redundancy and compensation in infectious disease phenotypes. Immunity (2011) 34:629-36. doi:10.1016/j.immuni.2011.05.009
26. Robinson MJ, Sancho D, Slack EC, LeibundGut-Landmann S, Reis e Sousa C. Myeloid C-type lectins in innate immunity. Nat Immunol (2006) 7:1258-65. doi:10.1038/ni1417
27. Durandy A, Kracker S, Fischer A. Primary antibody deficiencies. Nat Rev Immunol (2013) 13:519-33. doi:10.1038/nri3466
28. Shah P, Fatehchand K, Patel H, Fang H, Justiniano SE, Mo X, et al. Toll-like receptor 2 ligands regulate monocyte Fcgamma receptor expression and function. J Biol Chem (2013) 288:12345-52. doi:10.1074/jbc.M113.449983
29. Radstake TR, van Lent PL, Pesman GJ, Blom AB, Sweep FG, Ronnelid J, et al. High production of proinflammatory and Th1 cytokines by dendritic cells from patients with rheumatoid arthritis, and down regulation upon FcgammaR triggering. Ann Rheum Dis (2004) 63:696-702. doi:10.1136/ard.2003.010033
30. Ji JD, Tassiulas I, Park-Min KH, Aydin A, Mecklenbrauker I, Tarakhovsky A, et al. Inhibition of interleukin 10 signaling after Fc receptor ligation and during rheumatoid arthritis. J Exp Med (2003) 197:1573-83. doi:10.1084/jem.20021820
31. Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood (2009) 113:3716-25. doi:10.1182/blood-2008-09-179754
32. van Sorge NM, van der Pol WL, van de Winkel JG. FcgammaR polymorphisms: implications for function, disease susceptibility and immunotherapy. Tissue Antigens (2003) 61:189-202. doi:10.1034/j.1399-0039.2003.00037.x
33. Hepburn AL, Mason JC, Wang S, Shepherd CJ, Florey O, Haskard DO, et al. Both Fcgamma and complement receptors mediate transfer of immune complexes from erythrocytes to human macrophages under physiological flow conditions in vitro. Clin Exp Immunol (2006) 146:133-45. doi:10.1111/j.1365-2249.2006.03174.x
34. Allhorn M, Olin AI, Nimmerjahn F, Collin M. Human IgG/Fc gamma R interactions are modulated by streptococcal IgG glycan hydrolysis. PLoS One (2008) 3:e1413. doi:10.1371/journal.pone.0001413
35. Stemerding AM, Kohl J, Pandey MK, Kuipers A, Leusen JH, Boross P, et al. Staphylococcus aureus formyl peptide receptor-like 1 inhibitor (FLIPr) and its homologue FLIPr-like are potent FcgammaR antagonists that inhibit IgG-mediated effector functions. J Immunol (2013) 191:353-62. doi:10.4049/jimmunol.1203243
36. Du Clos TW, Mold C. The role of C-reactive protein in the resolution of bacterial infection. Curr Opin Infect Dis (2001) 14:289-93. doi:10.1097/00001432-200106000-00007
37. Mold C, Du Clos TW. C-reactive protein increases cytokine responses to Streptococcus pneumoniae through interactions with Fc gamma receptors. J Immunol (2006) 176:7598-604. doi:10.4049/jimmunol.176.12.7598
38. Wellington M, Dolan K, Haidaris CG. Monocyte responses to Candida albicans are enhanced by antibody in cooperation with antibody-independent pathogen recognition. FEMS Immunol Med Microbiol (2007) 51:70-83. doi:10.1111/j.1574-695X.2007.00278.x
39. Boonnak K, Dambach KM, Donofrio GC, Tassaneetrithep B, Marovich MA. Cell type specificity and host genetic polymorphisms influence antibody-dependent enhancement of dengue virus infection. J Virol (2011) 85:1671-83. doi:10.1128/JVI.00220-10
40. Chareonsirisuthigul T, Kalayanarooj S, Ubol S. Dengue virus (DENV) antibody-dependent enhancement of infection upregulates the production of anti-inflammatory cytokines, but suppresses anti-DENV free radical and pro-inflammatory cytokine production, in THP-1 cells. J Gen Virol (2007) 88:365-75. doi:10.1099/vir.0.82537-0
41. Modhiran N, Kalayanarooj S, Ubol S. Subversion of innate defenses by the interplay between DENV and pre-existing enhancing antibodies: TLRs signaling collapse. PLoS Negl Trop Dis (2010) 4:e924. doi:10.1371/journal.pntd.0000924
42. Ubol S, Phuklia W, Kalayanarooj S, Modhiran N. Mechanisms of immune evasion induced by a complex of dengue virus and preexisting enhancing antibodies. J Infect Dis (2010) 201:923-35. doi:10.1086/651018
43. Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol (2014) 14:36-49. doi:10.1038/nri3581
44. Posch W, Cardinaud S, Hamimi C, Fletcher A, Muhlbacher A, Loacker K, et al. Antibodies attenuate the capacity of dendritic cells to stimulate HIV-specific cytotoxic T lymphocytes. J Allergy Clin Immunol (2012) 130:1368-74. doi:10.1016/j.jaci.2012.08.025
45. Zhou J, Ludlow LE, Hasang W, Rogerson SJ, Jaworowski A. Opsonization of malaria-infected erythrocytes activates the inflammasome and enhances inflammatory cytokine secretion by human macrophages. Malar J (2012) 11:343. doi:10.1186/1475-2875-11-343
46. Randall LM, Engwerda CR. TNF family members and malaria: old observations, new insights and future directions. Exp Parasitol (2010) 126:326-31. doi:10.1016/j.exppara.2010.04.016
47. Klareskog L, Ronnelid J, Lundberg K, Padyukov L, Alfredsson L. Immunity to citrullinated proteins in rheumatoid arthritis. Annu Rev Immunol (2008) 26:651-75. doi:10.1146/annurev.immunol.26.021607.090244
48. Tsokos GC. Systemic lupus erythematosus. N Engl J Med (2011) 365:2110-21. doi:10.1056/NEJMra1100359
49. El Bannoudi H, Ioan-Facsinay A, Toes RE. Bridging autoantibodies and arthritis: the role of Fc receptors. Curr Top Microbiol Immunol (2014) 382:303-19. doi:10.1007/978-3-319-07911-0_14
50. Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) (2012) 51(Suppl 5):v3-11. doi:10.1093/rheumatology/kes113
51. Kokkonen H, Mullazehi M, Berglin E, Hallmans G, Wadell G, Ronnelid J, et al. Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis. Arthritis Res Ther (2011) 13:R13. doi:10.1186/ar3237
52. Quirke AM, Fisher BA, Kinloch AJ, Venables PJ. Citrullination of autoantigens: upstream of TNFalpha in the pathogenesis of rheumatoid arthritis. FEBS Lett (2011) 585:3681-8. doi:10.1016/j.febslet.2011.06.006
53. Tan Sardjono C, Mottram PL, van de Velde NC, Powell MS, Power D, Slocombe RF, et al. Development of spontaneous multisystem autoimmune disease and hypersensitivity to antibody-induced inflammation in Fcgamma receptor IIa-transgenic mice. Arthritis Rheum (2005) 52:3220-9. doi:10.1002/art.21344
54. van de Velde NC, Mottram PL, Powell MS, Lim B, Holmdahl R, Hogarth PM. Transgenic mice expressing human FcgammaRIIa have enhanced sensitivity to induced autoimmune arthritis as well as elevated Th17 cells. Immunol Lett (2010) 130:82-8. doi:10.1016/j.imlet.2009.12.005
55. Mathsson L, Lampa J, Mullazehi M, Ronnelid J. Immune complexes from rheumatoid arthritis synovial fluid induce FcgammaRIIa dependent and rheumatoid factor correlated production of tumour necrosis factor-alpha by peripheral blood mononuclear cells. Arthritis Res Ther (2006) 8:R64. doi:10.1186/ar1926
56. Mullazehi M, Mathsson L, Lampa J, Ronnelid J. Surface-bound anti-type II collagen-containing immune complexes induce production of tumor necrosis factor alpha, interleukin-1beta, and interleukin-8 from peripheral blood monocytes via Fc gamma receptor IIA: a potential pathophysiologic mechanism for humoral anti-type II collagen immunity in arthritis. Arthritis Rheum (2006) 54:1759-71. doi:10.1002/art.21892
57. Magnusson SE, Wennerberg E, Matt P, Lindqvist U, Kleinau S. Dysregulated Fc receptor function in active rheumatoid arthritis. Immunol Lett (2014) 162:200-6. doi:10.1016/j.imlet.2014.08.016
58. Goh FG, Midwood KS. Intrinsic danger: activation of toll-like receptors in rheumatoid arthritis. Rheumatology (Oxford) (2012) 51:7-23. doi:10.1093/rheumatology/ker257
59. Clavel C, Nogueira L, Laurent L, Iobagiu C, Vincent C, Sebbag M, et al. Induction of macrophage secretion of tumor necrosis factor alpha through Fcgamma receptor IIa engagement by rheumatoid arthritis-specific autoantibodies to citrullinated proteins complexed with fibrinogen. Arthritis Rheum (2008) 58:678-88. doi:10.1002/art.23284
60. Laurent L, Clavel C, Lemaire O, Anquetil F, Cornillet M, Zabraniecki L, et al. Fcgamma receptor profile of monocytes and macrophages from rheumatoid arthritis patients and their response to immune complexes formed with autoantibodies to citrullinated proteins. Ann Rheum Dis (2011) 70:1052-9. doi:10.1136/ard.2010.142091
61. Sokolove J, Zhao X, Chandra PE, Robinson WH. Immune complexes containing citrullinated fibrinogen costimulate macrophages via toll-like receptor 4 and Fcgamma receptor. Arthritis Rheum (2011) 63:53-62. doi:10.1002/art.30081
62. Suurmond J, Rivellese F, Dorjee AL, Bakker AM, Rombouts YJ, Rispens T, et al. Toll-like receptor triggering augments activation of human mast cells by anti-citrullinated protein antibodies. Ann Rheum Dis (2014). doi:10.1136/annrheumdis-2014-205562
63. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest (2012) 122:787-95. doi:10.1172/JCI59643
64. Wijngaarden S, van Roon JA, Bijlsma JW, van de Winkel JG, Lafeber FP. Fcgamma receptor expression levels on monocytes are elevated in rheumatoid arthritis patients with high erythrocyte sedimentation rate who do not use anti-rheumatic drugs. Rheumatology (Oxford) (2003) 42:681-8. doi:10.1093/rheumatology/keg174
65. Hepburn AL, Mason JC, Davies KA. Expression of Fcgamma and complement receptors on peripheral blood monocytes in systemic lupus erythematosus and rheumatoid arthritis. Rheumatology (Oxford) (2004) 43:547-54. doi:10.1093/rheumatology/keh112
66. Wenink MH, Santegoets KC, Roelofs MF, Huijbens R, Koenen HJ, van Beek R, et al. The inhibitory Fc gamma IIb receptor dampens TLR4-mediated immune responses and is selectively up-regulated on dendritic cells from rheumatoid arthritis patients with quiescent disease. J Immunol (2009) 183:4509-20. doi:10.4049/jimmunol.0900153
67. Torsteinsdottir I, Arvidson NG, Hallgren R, Hakansson L. Monocyte activation in rheumatoid arthritis (RA): increased integrin, Fc gamma and complement receptor expression and the effect of glucocorticoids. Clin Exp Immunol (1999) 115:554-60. doi:10.1046/j.1365-2249.1999.00817.x
68. Wijngaarden S, van de Winkel JG, Jacobs KM, Bijlsma JW, Lafeber FP, van Roon JA. A shift in the balance of inhibitory and activating Fcgamma receptors on monocytes toward the inhibitory Fcgamma receptor IIb is associated with prevention of monocyte activation in rheumatoid arthritis. Arthritis Rheum (2004) 50:3878-87. doi:10.1002/art.20672
69. Kim WU, Sreih A, Bucala R. Toll-like receptors in systemic lupus erythematosus; prospects for therapeutic intervention. Autoimmun Rev (2009) 8:204-8. doi:10.1016/j.autrev.2008.07.046
70. Karassa FB, Trikalinos TA, Ioannidis JP. Role of the Fcgamma receptor IIa polymorphism in susceptibility to systemic lupus erythematosus and lupus nephritis: a meta-analysis. Arthritis Rheum (2002) 46:1563-71. doi:10.1002/art.10306
71. Means TK, Latz E, Hayashi F, Murali MR, Golenbock DT, Luster AD. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest (2005) 115:407-17. doi:10.1172/JCI23025
72. Tel J, Beenhakker N, Koopman G, Hart B, Mudde GC, de Vries IJ. Targeted delivery of CpG ODN to CD32 on human and monkey plasmacytoid dendritic cells augments IFNalpha secretion. Immunobiology (2012) 217:1017-24. doi:10.1016/j.imbio.2012.01.016
73. Mehra S, Walker J, Patterson K, Fritzler MJ. Autoantibodies in systemic sclerosis. Autoimmun Rev (2013) 12:340-54. doi:10.1016/j.autrev.2012.05.011
74. Ciechomska M, Cant R, Finnigan J, van Laar JM, O'Reilly S. Role of toll-like receptors in systemic sclerosis. Expert Rev Mol Med (2013) 15:e9. doi:10.1017/erm.2013.10
75. Kim D, Peck A, Santer D, Patole P, Schwartz SM, Molitor JA, et al. Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-alpha activity with lung fibrosis. Arthritis Rheum (2008) 58:2163-73. doi:10.1002/art.23486
76. Tan FK, Zhou X, Mayes MD, Gourh P, Guo X, Marcum C, et al. Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology (Oxford) (2006) 45:694-702. doi:10.1093/rheumatology/kei244
77. Mavragani CP, Tzioufas AG, Moutsopoulos HM. Sjogren's syndrome: autoantibodies to cellular antigens. Clinical and molecular aspects. Int Arch Allergy Immunol (2000) 123:46-57. doi:10.1159/000024423
78. Pan M, Liu X, Zheng J. The pathogenic role of autoantibodies in pemphigus vulgaris. Clin Exp Dermatol (2011) 36:703-7. doi:10.1111/j.1365-2230.2011.04092.x
79. Weber MS, Hemmer B, Cepok S. The role of antibodies in multiple sclerosis. Biochim Biophys Acta (2011) 1812:239-45. doi:10.1016/j.bbadis.2010.06.009
80. Melief J, Koning N, Schuurman KG, Van De Garde MD, Smolders J, Hoek RM, et al. Phenotyping primary human microglia: tight regulation of LPS responsiveness. Glia (2012) 60:1506-17. doi:10.1002/glia.22370
81. Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med (2012) 367:2015-25. doi:10.1056/NEJMra1009433
82. Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol (2013) 13:176-89. doi:10.1038/nri3401
83. Bouhlal H, Martinvalet D, Teillaud JL, Fridman C, Kazatchkine MD, Bayry J, et al. Natural autoantibodies to Fcgamma receptors in intravenous immunoglobulins. J Clin Immunol (2014) 34(Suppl 1):S4-11. doi:10.1007/s10875-014-0019-2
84. Chu SY, Vostiar I, Karki S, Moore GL, Lazar GA, Pong E, et al. Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcgammaRIIb with Fc-engineered antibodies. Mol Immunol (2008) 45:3926-33. doi:10.1016/j.molimm.2008.06.027
85. Horton HM, Chu SY, Ortiz EC, Pong E, Cemerski S, Leung IW, et al. Antibody-mediated coengagement of FcgammaRIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus. J Immunol (2011) 186:4223-33. doi:10.4049/jimmunol.1003412
86. Chu SY, Yeter K, Kotha R, Pong E, Miranda Y, Phung S, et al. Suppression of rheumatoid arthritis B cells by XmAb5871, an anti-CD19 antibody that coengages B cell antigen receptor complex and Fcgamma receptor IIb inhibitory receptor. Arthritis Rheumatol (2014) 66:1153-64. doi:10.1002/art.38334
87. Szili D, Cserhalmi M, Banko Z, Nagy G, Szymkowski DE, Sarmay G. Suppression of innate and adaptive B cell activation pathways by antibody coengagement of FcgammaRIIb and CD19. MAbs (2014) 6:991-9. doi:10.4161/mabs.28841
88. Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med (2010) 363:1303-12. doi:10.1056/NEJMoa1000500
89. Benoit M, Desnues B, Mege JL. Macrophage polarization in bacterial infections. J Immunol (2008) 181:3733-9. doi:10.4049/jimmunol.181.6.3733
90. Heusinkveld M, van der Burg SH. Identification and manipulation of tumor associated macrophages in human cancers. J Transl Med (2011) 9:216. doi:10.1186/1479-5876-9-216
91. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer (2012) 12:278-87. doi:10.1038/nrc3236
92. Suurmond J, Stoop JN, Rivellese F, Bakker AM, Huizinga TW, Toes RE. Activation of human basophils by combined toll-like receptor-and FcepsilonRI-triggering can promote Th2 skewing of naive T helper cells. Eur J Immunol (2014) 44:386-96. doi:10.1002/eji.201343617
93. Janczy JR, Ciraci C, Haasken S, Iwakura Y, Olivier AK, Cassel SL, et al. Immune complexes inhibit IL-1 secretion and inflammasome activation. J Immunol (2014) 193:5190-8. doi:10.4049/jimmunol.1400628
94. Sutterwala FS, Noel GJ, Salgame P, Mosser DM. Reversal of proinflammatory responses by ligating the macrophage Fcgamma receptor type I. J Exp Med (1998) 188:217-22. doi:10.1084/jem.188.1.217
95. Gerber JS, Mosser DM. Reversing lipopolysaccharide toxicity by ligating the macrophage Fc gamma receptors. J Immunol (2001) 166:6861-8. doi:10.4049/jimmunol.166.11.6861
96. Bandukwala HS, Clay BS, Tong J, Mody PD, Cannon JL, Shilling RA, et al. Signaling through Fc gamma RIII is required for optimal T helper type (Th)2 responses and Th2-mediated airway inflammation. J Exp Med (2007) 204:1875-89. doi:10.1084/jem.20061134
97. Zhang Y, Liu S, Liu J, Zhang T, Shen Q, Yu Y, et al. Immune complex/Ig negatively regulate TLR4-triggered inflammatory response in macrophages through Fc gamma RIIb-dependent PGE2 production. J Immunol (2009) 182:554-62. doi:10.4049/jimmunol.182.1.554
98. Gallo P, Goncalves R, Mosser DM. The influence of IgG density and macrophage Fc (gamma) receptor cross-linking on phagocytosis and IL-10 production. Immunol Lett (2010) 133:70-7. doi:10.1016/j.imlet.2010.07.004